Johnson & Johnson Earnings: Can Pharma Keep Stoking Growth?

The health-care conglomerate has relied on pharmaceuticals for much of its overall growth prospects. Will the trend continue?

Jul 14, 2014 at 7:00AM

On Tuesday, Johnson & Johnson (NYSE:JNJ) will release its quarterly report, and shareholders have been pleased with the stock's ascent to all-time record levels recently. Despite Johnson & Johnson having a wide array of health-care-related businesses spanning medical devices and consumer over-the-counter products, the company has emphasized the growth potential of its pharmaceutical unit. By doing so, Johnson & Johnson seeks to tap into the same trends that have helped peers Pfizer (NYSE:PFE) and Merck (NYSE:MRK) start reversing the effects of their patent cliffs and bolster their future prospects.

Johnson & Johnson has a global reputation in the health-care space, with well-known products like its Band-Aid and Tylenol brands in millions of household medicine cabinets. Yet the pharmaceutical space has seemed to have the most promise for J&J lately, with a number of high-potential drugs in its pipeline that could help boost revenue for years to come. Let's take an early look at what's been happening with Johnson & Johnson over the past quarter and what we're likely to see in its report.

Source: Johnson & Johnson.

Stats on Johnson & Johnson

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$18.86 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Can Johnson & Johnson earnings surpass expectations again?
In recent months, investors have boosted their views on Johnson & Johnson earnings, raising estimates for the second quarter by 2% and full-year projections for this year and next by about 1%. The stock has kept up its climb, gaining almost 9% since early April.

Johnson & Johnson's first-quarter earnings report continued the company's recent trend of getting growth primarily from its pharmaceutical division. Pharma sales jumped 11%, compared to relatively flat performance in the medical-device area and a slight decline of 3% in consumer-products sales. In particular, the performances of arthritis and psoriasis treatment Stelara and prostate-cancer drug Zytiga were extremely strong, with sales gains of 32% and 49% respectively compared to year-ago levels. High margins on prescription drugs helped send net income up almost 8%.


Yet one thing that Johnson & Johnson can count on in the pharma arena is competition. J&J's Invokana treatment for diabetes has enjoyed early success, and given the size of the diabetes market, it could easily become a blockbuster in time. Yet Merck and Pfizer have worked to develop their own version of a treatment that inhibits the SGLT2 protein, with ertugliflozin in phase 3 trials. Other companies are working at other diabetes treatments that could potentially endanger Johnson & Johnson's position in the space.

Johnson & Johnson hasn't given up on hopes for growth in other areas, though. In May, the company said that it still sees medical devices as a growth industry, especially in emerging markets around the world. Yet rather than simply expanding for expansion's sake, Johnson & Johnson expects to make targeted forays into areas where it can get the best results, with its current emphasis on surgical instruments and orthopedics likely to continue, combined with some tactical plays in other high-value areas like diabetes insulin-management equipment. In contrast to Merck and Pfizer, though, it seems unlikely that J&J will join the recent string of massive buyout offers just to make its business bigger.

One thing investors need to focus on with Johnson & Johnson is its valuation. J&J has a reputation as being a defensive stock, appropriate for those looking to reduce risk in a choppy market. Yet the stock's record run has pushed its trailing earnings multiple above 20, and even its 2.7% dividend yield won't necessarily provide the same level of downside protection that the health-care stalwart has in past markets when its valuation wasn't quite as high.

In the Johnson & Johnson earnings report, watch to see how much of the company's growth again relies on pharmaceuticals. At some point, if the other businesses can't catch up, then Johnson & Johnson will likely see pressure to restructure itself and possibly spin off underperforming businesses into separate companies. With the share price so high, J&J doesn't have much margin for error in its report.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multibagger returns you will need The Motley Fool's new free report on the Dream Team responsible for this game-changing blockbuster. CLICK HERE NOW.

Click here to add Johnson & Johnson to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers